Lisocabtagene Maraleucel,ibrutinib,venetoclax
Bms,Roche,Abbvie
['lymphoma', 'liso-cel', 'lymsm', 'cll', 'transcend cll 004', 'cll 004', 'transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)']
transcend cll 004 liso-cel for r/r cll presented at #asco23 lymphoma session &amp; published in today: orr: 47%
crr 18% (pr 29%)
interestingly umrd 59%, as there were patients who had stable disease by response criteria but umrd
#lymsm 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem